The major goals of pharmacologic<unk> for patients with HFrEF are reducing mortality, reducing the risk of repeated hospitalizations due to worsening HF, and improving clinical status, functional capacity, and quality of life. The mainstay of<unk> for HFrEF  is the modulation of the [[renin-angiotensin-aldosterone] system] (RAAS) and sympathetic nervous system.
Congestive heart failure Pharmacological treatments for patients with heart failure with reduced ejection fraction
Congestive heart failure treatment of patients with current or prior symptoms of heart failure 
Congestive heart failure treatment of patients with cardiac structural abnormalities or remodeling who have not developed heart failure symptoms 
Congestive heart failure treatment of patients at high risk for developing heart failure 
Congestive heart failure Treatment of Heart failure with preserved ejection fraction
Class III recommendations in guidelines for cardiovascular medicine list of guidelines
Congestive heart failure angiotensin receptor-neprilysin inhibitor
Unstable angina / non ST elevation myocardial infarction inhibitors of RAS